J & J, Arrowhead partner on gene-silencing drug

Johnson& Johnson ’s Janssen Pharmaceuticals has entered into an agreement with Arrowhead Pharmaceuticals for an exclusive, worldwide license to develop and commercialize a therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news